| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 19, 2008
Accepted on June 23, 2009
Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK; Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, USA; Leuven University Center for Metabolic Bone Diseases and Division of Geriatric Medicine, Katholieke Universiteit Leuven, Leuven, Belgium; Rheumatologic Rehabilitation Unit, University of Verona, Verona, Italy; Centre of Muscle and Bone Research, Free University and Humboldt-University, Berlin, Germany; Osteoporosis Policlinic, University Hospital and University of Bern, Bern, Switzerland; California Pacific Medical Center Research Institute, University of California, San Francisco, USA; INSERM Research Unit 831 and University of Lyon, Lyon, France; Novartis Pharmaceuticals Corporation, East Hanover, USA; Department of Epidemiology, University of Pittsburgh, Pittsburgh, USA
* To whom correspondence should be addressed. E-mail: r.eastell{at}sheffield.ac.uk.
Context: In the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly – Pivotal Fracture Trial (HORIZON-PFT), zoledronic acid (ZOL) 5 mg significantly reduced fracture risk.
Objective: To identify factors associated with greater efficacy during ZOL 5 mg treatment.
Design, Setting and Patients: Subgroup analysis (preplanned and post hoc) of a multicenter, double-blind, placebo-controlled, 36-month trial in 7765 women with postmenopausal osteoporosis.
Intervention: Single infusion of ZOL 5 mg or placebo at baseline, 12 and 24 months.
Main Outcome Measures: Primary endpoints: new vertebral fracture and hip fracture. Secondary endpoints: non-vertebral fracture, change in femoral neck bone mineral density (BMD). Baseline risk factor subgroups: age, BMD T-score and vertebral fracture status, total hip BMD, race, weight, geographical region, smoking, height loss, history of falls, physical activity, prior bisphosphonates, creatinine clearance, body mass index (BMI), concomitant osteoporosis medications.
Results: Greater ZOL induced effects on vertebral fracture risk with younger age (treatment-by-subgroup interaction P=0.05), normal creatinine clearance (P=0.04), and BMI 
25 kg/m2 (P=0.02). There were no significant treatment–factor interactions for hip or non-vertebral fracture or for change in BMD.
Conclusions: ZOL appeared more effective in preventing vertebral fracture in younger women, overweight/obese women and women with normal renal function. ZOL had similar effects irrespective of fracture risk factors or femoral neck BMD.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
